

Getting to Know Sandostatin® LAR Depot (octreotide acetate) for Injectable Suspension

Hi, I'm Sandy, your Sandostatin LAR Depot RealSupport™ sidekick. If you have severe diarrhea and flushing associated with carcinoid syndrome, you are not alone. RealSupport™ is here with information and tools that can help you learn how to manage symptoms.

Once you're diagnosed with carcinoid syndrome, getting control of the flushing and diarrhea is an important next step. Your doctor will recommend a treatment, such as Sandostatin® LAR Depot (octreotide acetate) for injectable suspension to help manage your severe diarrhea and flushing.

Sandostatin LAR Depot may be able to help. Let's talk a little about what Sandostatin LAR Depot is used for, what it takes to get started, and some steps you and your doctor can take to help control your symptoms.

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is a prescription medicine for the long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors. In patients with carcinoid syndrome, the effect of Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.

Sandostatin is available in 2 formulations. Your health care provider gives you Sandostatin LAR Depot once a month by injecting it into the buttocks (intragluteal injection). Sandostatin® (octreotide acetate) Immediate-Release Injection is the same medicine. But you self-inject this formula 2 to 4 times per day under the skin of the thigh, upper arm, or abdomen.

Your doctor will decide if Sandostatin LAR Depot is right for you based on how your body responds to Sandostatin Immediate-Release Injection.

Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

Please watch this video in its entirety for additional Important Safety Information.

If you've never taken Sandostatin LAR Depot, your doctor may first give you Sandostatin Immediate-Release injection for 2 weeks, just to see how you respond to the medicine.

Once your doctor is satisfied with the way you're responding to the immediate-release Sandostatin injection, they will most likely change your treatment to Sandostatin LAR Depot.

The most common side effects of Sandostatin LAR Depot include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

After that, you must work closely with your health care provider to follow your treatment plan and stop by their office for your monthly Sandostatin LAR Depot treatment.

We understand that it may be difficult for some patients to leave their home for doctor visits. Go to us.sandostatin.com/MAP to see if you're eligible to have your monthly medicine given at home by a trained nurse.

What happens if you experience symptoms or side effects related to your treatment? Tell your doctor everything! Some people even use a daily journal to keep track of their symptoms so they don't forget anything between visits. You can download a journal at us.sandostatin.com/journal.

Your doctor may also ask about your diet to make sure you're not eating or drinking something that could trigger symptoms of severe diarrhea and flushing related to your carcinoid syndrome.

RealSupport™ can help with that, too. We have simple recipes and more videos about food choices to help you find ways to limit your symptoms. Stop by anytime!

By the way, did you know that you may be eligible for immediate co-pay savings on your next prescription?

Go to us.sandostatin.com/resources to learn more.

Sandostatin LAR Depot is the number one prescribed medicine of its kind in the world.

Approved Use and Important Safety Information

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension

INDICATIONS AND USAGE

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® (octreotide acetate)

Injection has been shown to be effective and tolerated for

- Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
- Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors

In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

Before Taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Common Side Effects: Most patients experience side effects at some time. Some common side effects you may experience include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

Other Information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please [click here](#) for full Prescribing Information.



Novartis Pharmaceuticals Corporation
East Hanover, New Jersey, 07936-1080

© 2020 Novartis



8/20

SDS-1231505